Price (delayed)
$0.7469
Market cap
$61.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.83
Enterprise value
$6.23M
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The
There are no recent dividends present for NGM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.